Table 3.
Barrett’s oesophagus during follow up in patients treated with single dose ALA-PDT (PDT100), fractionated dose ALA-PDT (PDT20+100), or APC, in some patients followed by treatment with APC for residual Barrett’s oesophagus
| Follow up (months) | PDT100 group | PDT20+100 group | APC group | |||
| Endoscopic BO (%) | Histological BO (%) | Endoscopic BO (%) | Histological BO (%) | Endoscopic BO (%) | Histological BO (%) | |
| 6 | 0/13 | 1/13 (8) | 0/12 | 0/12 | 1/14 (7) | 3/14 (21) |
| 12 | 1/11 (9) | 2/11 (18) | 0/10 | 1/10 (10) | 2/12 (17) | 4/12 (33) |
| 18 | 2/8 (25) | 2/8 (25) | 0/8 | 1/8 (12) | 2/9 (22) | 3/9 (33) |
| 24 | NA | NA | 0/2 | 0/2 | NA | NA |
*NA, not applicable.
ALA, 5-aminolevulinic acid; APC, argon plasma coagulation; BO, Barrett’s oesophagus; PDT, photodynamic therapy.
No significant differences between the groups.